Cognition Therapeutics, Inc. (NASDAQ:CGTX) Stock Has Consensus Target Price of $3.33 According to Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have earned an average rating of “Moderate Buy” from the four analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.33.

Several research firms have weighed in on CGTX. HC Wainwright reissued a “buy” rating on shares of Cognition Therapeutics in a research report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Hedge Funds Weigh In On Cognition Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CGTX. Sigma Planning Corp lifted its position in Cognition Therapeutics by 7.3% during the 2nd quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock worth $417,000 after acquiring an additional 24,500 shares during the period. Corient Private Wealth LP acquired a new position in shares of Cognition Therapeutics in the second quarter valued at about $93,000. Tocqueville Asset Management L.P. acquired a new position in shares of Cognition Therapeutics in the second quarter valued at about $369,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cognition Therapeutics in the second quarter valued at about $165,000. Finally, BlackRock Inc. purchased a new position in shares of Cognition Therapeutics in the second quarter worth about $1,451,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Trading Up 4.0%

Shares of CGTX stock traded up $0.03 during trading hours on Tuesday, reaching $0.89. 2,308,070 shares of the company’s stock were exchanged, compared to its average volume of 1,029,535. Cognition Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.00. The stock has a market cap of $84.73 million, a PE ratio of -5.26 and a beta of 1.80. The stock’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.07.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, equities analysts expect that Cognition Therapeutics will post -0.30 EPS for the current fiscal year.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurodegenerative diseases that affect memory, cognition and behavior. The company’s research centers on drug candidates designed to protect or restore synaptic function, which is important for communication between nerve cells.

Cognition Therapeutics’ lead investigational product is CT1812, an orally administered, brain-penetrant small molecule designed to modulate the sigma-2 receptor complex.